Evidence map›Paper›PMID 40822333›Full record

ArticleiScience2025

A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer.

Shusuan Jiang, Ye Tian, Hongqian Guo, Jianming Guo, Haiying Dong, Hong Luo, Wei Xue, Tao Xu, Lei Li, Mingxing Qiu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shusuan JiangDepartment of Urology, Hunan Cancer Hospital, Changsha, Hunan, China.
Ye TianDepartment of Urology, Beijing Friendship Hospital, Beijing, China.
Hongqian GuoDepartment of Urology, Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Haiying DongDepartment of Urology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Hong LuoDepartment of Urology, Chongqing University Cancer Hospital, Chongqing, China.
Wei XueDepartment of Urology, Shanghai Jiaotong University School of Medicine Renji Hospital, Shanghai, China.
Tao XuDepartment of Urology, Peking University People's Hospital, Beijing, China.
Lei LiDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi' an, Shaanxi, China.
Mingxing QiuDepartment of Urology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Liping XieDepartment of Urology, The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
Angela Lopez-GitlitzClinical Development, Johnson & Johnson, Los Angeles, CA, USA.
Sharon McCarthyClinical Development, Johnson & Johnson, Spring House, PA, USA.
Yanmei LiuClinical Development, Johnson & Johnson, Beijing, China.
Haocheng MaClinical Development, Johnson & Johnson, Beijing, China.
Hongchuan LiangStatistics and Decision Sciences, Johnson & Johnson, Shanghai, China.
Yanhui LiMedical Affairs Delivery Unit, Johnson & Johnson, Beijing, China.
Na ChenMedical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This post-approval commitment study addressed the limited data on the safety and efficacy of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Utilizing a double-blinded, placebo-controlled trial with pre-planned crossover design, 75 patients were randomized (2:1) to receive apalutamide 240 mg daily or placebo while continuing androgen deprivation therapy. Apalutamide significantly reduced the risk of prostate-specific antigen (PSA) progression by 76.7% compared with placebo (hazard ratio [HR] = 0.233,

Indexed as

Clinical medicineOncologyTherapeutics

Identifiers

PMID40822333
PMCPMC12355417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.